Gary D. Novack, Ph.D.
Clinical Professor
Locations and Contact
Additional Numbers
Physician Referrals
Research/Academic Interests
Dr. Novack is a board-certified clinical pharmacologist with decades of experience in ophthalmic product development. He works with innovators in novel therapeutics to aid in development of new products. He has extensive interactions with government regulatory affairs. His research interests include patient adherence and performance, therapeutics, myopia prophylaxis, dry eye disease and glaucoma.
Division
Ophthalmology
Center/Program Affiliation
Undergraduate School
B.A., UC Santa Cruz, Santa Cruz CA 1973
Other School
Ph.D., Pharmacology, UC Davis, Davis CA 1977
Fellowship
Neurophysiology, UCLA, Los Angeles CA 1977-1979
Association for Research in Vision and Ophthalmology: Dr. Roger Vogel Award for Pharmaceutical Research, 2018
Merle Greene Robertson Award for Service to Society, Robert Louis Stevenson School, 2010
American Academy of Ophthalmology Achievement Award, 2007
Earl C. Anthony Fellow in Pharmacology, 1976, 1977
Honors in Major, UC Santa Cruz, 1973
Zarbin MA, Novack G. N-of-1 Clinical Trials: A Scientific Approach to Personalized Medicine for Patients with Rare Retinal Diseases Such as Retinitis Pigmentosa. J Ocul Pharmacol Ther. 2021 Nov;37(9):495-501. doi:10.1089/jop.2021.0059. Epub 2021 Sep 3. PMID:34491833.
Novack GD. Eyes on New Product Development. J Ocul Pharmacol Ther. 2021 Oct;37(8):439-440. doi:10.1089/jop.2021.29084.gdn. Epub 2021 Aug 26. PMID:34448621.
Lee EH, Novack GD. Compounded medications for ocular surface disease. Ocul Surf. 2021 Oct;22:267-270. doi:10.1016/j.jtos.2021.09.004. Epub 2021 Sep 20. PMID:34555526.
Novack GD. Eyes on New Product Development. J Ocul Pharmacol Ther. 2021 Sep;37(7):383-385. doi:10.1089/jop.2021.29083.gdn. Epub 2021 Jul 27. PMID:34314623.
Novack GD. Unapproved drugs - A fix to an unintended consequence of an FDA policy. Ocul Surf. 2021 Jul;21:351-354. doi:10.1016/j.jtos.2021.05.002. Epub 2021 May 13. PMID:33992810.
Novack GD, Moshiri A. Off-Label Use as a Standard of Care. Am J Ophthalmol. 2021 Apr;224:A6-A8. doi:10.1016/j.ajo.2020.09.014. Epub 2020 Oct 14. PMID:33068530.
Novack GD. Regulatory and Developmental Aspects of Biomarkers in the Treatment of Ocular Surface Disease. Eye Contact Lens. 2020 Mar;46 Suppl 2:S106-S108. doi:10.1097/ICL.0000000000000639. PMID:31283553.
Novack G. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Am J Ophthalmology. 2019. doi:10.1016/j.ajo.2019.01.003.
Novack GD. How a drug developer thinks about a new ophthalmic product. Ocul Surf. 2018 Jul;16(3):390-392. doi:10.1016/j.jtos.2018.05.005. Epub 2018 May 23. PMID:29800751.
Novack GD. A Drug to Prevent Pediatric Myopia-What Would it Take? Eye Contact Lens. 2018 Jul;44(4):220-223. doi:10.1097/ICL.0000000000000498. PMID:29554028.